Bioretec Oy Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Alan Donze

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	1.7yrs

Recent management updates

Recent updates

CEO

Alan Donze (59 yo)

less than a year

Tenure

Mr. Alan Donze is Chief Executive Officer of Bioretec Oy from May 20, 2024. Mr. Donze has held senior leadership positions for a number of other medical device and technology companies including Smith Neph...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Alan Donze	Chief Executive Officer	less than a year	no data	no data
Johanna Salko	Chief Financial Officer	3.8yrs	no data	no data
Esa Hallinen	Director of Operations	1.3yrs	no data	no data
Timo Lehtonen	Chief Technology Officer	less than a year	no data	no data
Rami Ojala	Sales & Marketing Director	2.8yrs	no data	no data

1.3yrs

Average Tenure

57yo

Average Age

Experienced Management: BRETEC's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Tomi Numminen	Chairman of the Board	8.5yrs	no data	no data
Kustaa Poutiainen	Director	1.5yrs	no data	no data
Sarah Van Hellenberg Hubar-Fisher	Director	3.6yrs	no data	no data
Michael Piccirillo	Director	6.8yrs	no data	no data
Paivi Malinen	Director	2.6yrs	no data	no data
Klaus Dresing	Member of Scientific Advisory Board	no data	no data	no data
Fan Liu	Member of Scientific Advisory Board	1.7yrs	no data	no data
Theddy Slongo	Member of Scientific Advisory Board	no data	no data	no data
Jeffrey Wang	Member of Scientific Advisory Board	1.7yrs	no data	no data
Richard Assaker	Member of Scientific Advisory Board	1.7yrs	no data	no data
Stefan Rammelt	Member of Scientific Advisory Board	1.3yrs	no data	no data
Verena Schreiber	Member of Scientific Advisory Board	1.3yrs	no data	no data

1.7yrs

Average Tenure

53yo

Average Age

Experienced Board: BRETEC's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

Bioretec Oy Management

Management criteria checks 0/4

Key information

Recent management updates

Bioretec Oy Shareholders' Nomination Board Appointed

Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors

Bioretec Ltd Announces CEO Changes

Bioretec Ltd Unveils Its Revitalized Scientific Advisory Board

Bioretec Oy Appoints Esa Hallinen as Director of Operations and Member of the Management Team

Bioretec Oy Approves Management Appointments

Recent updates

Bioretec Ltd. Updates Its Product Development Strategy by Accelerating the Product Development of RemeOs™? Spinal Interbody Cage

Bioretec Oy Shareholders' Nomination Board Appointed

Bioretec Ltd. Reports Successful Clinical Outcomes from U.S. Controlled Launch of RemeOs Trauma Screw

Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors

Bioretec Ltd. Receives a Patent by the U.S. Patent Office for its RemeOs Magnesium Alloy Composition

Bioretec Has Been Granted FDA Breakthrough Device Designation Status for its RemeOs Spinal Interbody Cage

New minor risk - Share price stability

Bioretec's European Market Authorization for RemeOs Trauma Screw Proceeded to Expert Panel Evaluation

Bioretec Oy to Report Q2, 2024 Results on Aug 15, 2024

Bioretec Ltd Announces CEO Changes

Bioretec Estimates the Approval of the European Market Authorization for the Biodegradable RemeOs™ Trauma Screw Will Move to the First Quarter of 2024

Bioretec Estimates the Approval of the European Market Authorization for the Biodegradable RemeOs™ Trauma Screw Will Move to the First Quarter of 2024

Bioretec Ltd Unveils Its Revitalized Scientific Advisory Board

Bioretec Oy Appoints Esa Hallinen as Director of Operations and Member of the Management Team

Bioretec Oy Approves Management Appointments

Bioretec Ltd Appoints Dr. Jeremy Dublon as Regulatory Advisor

Bioretec Ltd Submits Additional Information Requested by the FDA for US Registration of RemeOs Trauma Screws

Bioretec Oy to Report First Half, 2023 Results on Aug 11, 2023

No independent directors

Bioretec Ltd, Updates Estimate of U.S. registration of RemeOs™ Screws and Expects Approval in April 2023

Bioretec's Hybrid Composite Patent Has Been Approved in Europe

Bioretec Oy Announces ActivaPin Bioresorbable Implant Provides Good Alternative Treatment of Pediatric Elbow Injuries

Bioretec Ltd Announces Bioresorbable Activa IM-Nail™ Shows Convincing Results in Post-Market Clinical Follow Up Study for the Treatment of Children's Forearm Fractures

Bioretec Ltd Submits Market Authorization Request for Its Bioresorbable RemeOs™ Magnesium Screw in the U.S

No independent directors

Bioretec's ActivaPin(TM) Bioresorbable Implant Provides Excellent Clinical Outcome in the Treatment of Pediatric Wrist Fractures

Bioretec Oy Announces Appointment of Päivi Malinen as Member of the Board of Directors

Bioretec Oy has completed an IPO in the amount of €1.74 million.

No independent directors

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age